Publications by authors named "Peter Wolna"

Claim this Profile
O
Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Andreas Johne, Holger Scheible, Andreas Becker, Jan Jaap van Lier, Peter Wolna

Invest New Drugs· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Daniela Willen, Wolfgang Uhl, Peter Wolna, Orestis Papasouliotis, Özkan Yalkinoglu

Eur J Drug Metab Pharmacokinet· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo- and Racemic Praziquantel: Two Phase I Studies.
Wilhelmina Maria Bagchus, Deon Bezuidenhout, Eleanor Harrison-Moench, Elly Kourany-Lefoll, Peter Wolna

Clin Transl Sci· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose pharmacokinetic study comparing the pharmacokinetics of recombinant human chorionic gonadotropin in healthy Japanese and Caucasian women and recombinant human chorionic gonadotropin and urinary human chorionic gonadotropin in healthy Japanese women.
Wilhelmina Bagchus, Peter Wolna, Wolfgang Uhl

Reprod Med Biol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris) in Pituitary-Suppressed Healthy Women.
Wilhelmina Bagchus, Özkan Yalkinoglu, Peter Wolna

Front Endocrinol (Lausanne)· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials.
Ulrike Gottwald-Hostalek, Wolfgang Uhl, Peter Wolna, George J Kahaly

Curr Med Res Opin· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm.
Sonja Krösser, Peter Wolna, Tanya Z Fischer, Ursula Boschert, Randall Stoltz

J Clin Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.
Sonja Krösser, Anne Marquet, Dieter Gallemann, Peter Wolna, Nicolas Fauchoux

Biopharm Drug Dispos· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation.
Bernd Liedert, Ulf Forssmann, Peter Wolna, Michaela Golob, Andreas Kovar

BMC Clin Pharmacol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency.
Wolfgang Vanscheidt, Volker Jost, Peter Wolna, Peter W Lücker, Alfred Müller

Arzneimittelforschung· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis